company mission and gene therapy platform vision
Very little changed. In both 2019 and 2020, Minicircle says the same core thing: its mission is to relieve suffering and enrich the human condition through safe, accessible gene therapy. The platform vision is also basically unchanged. It is still pitched as a human genetic enhancement system for long-lasting, reversible expression of intercellular proteins without changing the person’s existing genome. What did change? Mostly wording polish, not doctrine. The 2019 version says it is "pioneering" the platform; the 2020 version calls it "an advanced form" of enhancement. That is cosmetic. The underlying claims about safety, accessibility, reversibility, durability, and non-alteration of the pre-existing genome remain intact. So the belief evolution here is thin to nonexistent. This looks less like a strategic shift and more like copy editing. There is no evidence in these two snapshots of a changed mission, narrowed scope, new technical thesis, or retreat from the enhancement framing. Evidence is thin because there are only two statements, and they are near-duplicates. If there was a real change, it is not visible here.